Condition
Sodium-GLucose coTransporter-2 Inhibitors
Total Trials
4
Recruiting
3
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (1)
P 4 (1)
Trial Status
Recruiting3
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07482943Phase 4Recruiting
The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
NCT05715814Phase 3Recruiting
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
NCT05344963CompletedPrimary
Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors
NCT06398977Not ApplicableRecruiting
Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
Showing all 4 trials